NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Observational Study to Monitor Safety and Effectiveness of Obinutuzumab in Follicular Lymphoma or Previously Untreated Chronic Lymphocytic Leukemia

NCT03374137

CompletedN/A

Sponsor: Hoffmann-La Roche

Conditions: Chronic Lymphocytic Leukemia, Follicular Lymphoma

Interventions: obinutuzumab

Countries: South Korea

This study aims to collect clinical data, mainly focused on safety, in the local target population as per the requirement of Korea Ministry of Food and Drug Safety for market authorization. The study population comprises patients with approved local indications chronic lymphocytic leukemia (CLL) and/or follicular lymphoma (FL) in routine clinical practice after launch.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Administered obinutuzumab under the approved indications in Korea at investigator's discretion
* Previously untreated with obinutuzumab

Exclusion Criteria:

* Out-of locally approved indications, dosage, and administration
* Pregnant women, breastfeeding women
* Hepatic disease
* Participate in other clinical trials

Locations (17)

Busan, South Korea
Busan, South Korea
Gyeonggi-do, South Korea
Gyeonggi-do, South Korea
Incheon, South Korea
Incheon, South Korea
Seoul, South Korea
Seoul, South Korea
Seoul, South Korea
Seoul, South Korea
Seoul, South Korea
Seoul, South Korea
Seoul, South Korea
Seoul, South Korea
Seoul, South Korea
Seoul, South Korea
Wŏnju, South Korea